ZA200106256B - Regulation of anaesthesia. - Google Patents
Regulation of anaesthesia. Download PDFInfo
- Publication number
- ZA200106256B ZA200106256B ZA200106256A ZA200106256A ZA200106256B ZA 200106256 B ZA200106256 B ZA 200106256B ZA 200106256 A ZA200106256 A ZA 200106256A ZA 200106256 A ZA200106256 A ZA 200106256A ZA 200106256 B ZA200106256 B ZA 200106256B
- Authority
- ZA
- South Africa
- Prior art keywords
- dsip
- anaesthesia
- delta
- compound
- anaesthetic
- Prior art date
Links
- 206010002091 Anaesthesia Diseases 0.000 title claims description 57
- 230000037005 anaesthesia Effects 0.000 title claims description 57
- 238000001949 anaesthesia Methods 0.000 title claims description 57
- 230000033228 biological regulation Effects 0.000 title description 5
- ZRZROXNBKJAOKB-GFVHOAGBSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-[[(2s)-2-amino-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanedioic acid Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 ZRZROXNBKJAOKB-GFVHOAGBSA-N 0.000 claims description 118
- 108010051088 Delta Sleep-Inducing Peptide Proteins 0.000 claims description 118
- 150000001875 compounds Chemical class 0.000 claims description 67
- 230000003444 anaesthetic effect Effects 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 47
- 229940124326 anaesthetic agent Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 15
- 239000003193 general anesthetic agent Substances 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 206010039897 Sedation Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000036280 sedation Effects 0.000 claims 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 21
- 229960004134 propofol Drugs 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000000556 agonist Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 230000004622 sleep time Effects 0.000 description 8
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 7
- 206010038678 Respiratory depression Diseases 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000007177 brain activity Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000003227 neuromodulating effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006266 hibernation Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102400000988 Met-enkephalin Human genes 0.000 description 2
- 108010042237 Methionine Enkephalin Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000008667 sleep stage Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 description 1
- COHPSYLINFUPSS-HHHIRMLJSA-N (2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 COHPSYLINFUPSS-HHHIRMLJSA-N 0.000 description 1
- IMJJGZJYONIGJK-LIHMJOFSSA-N 3-[(2S,8S,11S,20S,23S,26S)-20-(carboxymethyl)-26-(hydroxymethyl)-8-(1H-indol-3-ylmethyl)-11,23-dimethyl-3,6,9,12,15,18,21,24,27,30-decaoxo-1,4,7,10,13,16,19,22,25,28-decazacyclotriacont-2-yl]propanoic acid Chemical compound C[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)CNC1=O IMJJGZJYONIGJK-LIHMJOFSSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000011714 Glycine Receptors Human genes 0.000 description 1
- 108010076533 Glycine Receptors Proteins 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108700029591 cyclo-Gly- delta-sleep-inducing peptide Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940072271 diprivan Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- COHPSYLINFUPSS-UHFFFAOYSA-N neo-kyotorphin Natural products CC(O)C(N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 COHPSYLINFUPSS-UHFFFAOYSA-N 0.000 description 1
- 108010072397 neo-kyotorphin Proteins 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
RE WO 00/45832 PCT/GB00/00281 'y 1
REGULATION OF ANAESTHESIA
The present invention relates to the regulation of anaesthesia and also a ‘ method of evaluating the anaesthetic needs of a subject.
The metabolic activity of the brain changes in various clinical situations. For example the metabolic activity of the brain is increased during an epileptic fit and during rapid eye movement sleep. In contrast the metabolic activity of the brain is reduced during hibernation and during the administration of a general anaesthetic.
Anaesthesia may be defined as a loss of feeling or insensibility to external stimuli. Anaesthesia may be local (the loss of sensation in a specific tissue) or general ‘ (when it is generally associated with a lack of consciousness). Studies have shown that a reduction in brain metabolism of some 47% is associated with a state of general - anaesthesia. Administration of excessive doses of anaesthetic compounds leads to a : reduction in metabolic activity in excess of this level and a depth of anaesthesia that is excessive and associated with an increased risk of side-effects. It is therefore particularly important for a clinician to be able to reliably and sensitively regulate . brain activity to allow the induction of controlled anaesthesia. :
A state of anaesthesia is physiologically different to sleep. For instance, a subject who is asleep may be easily roused and therefore remains sensitive to external stimuli whereas a subject under a general anaesthetic may not be roused to consciousness by external stimuli. Furthermore sleep is not necessarily associated with reduced brain activity (e.g. during Rapid Eye Movement sleep, brain activity is normally high) whereas general anaesthetic is associated with reduced activity. Given the differences between anaesthesia and sleep it is not surprising that anaesthetic compounds do not necessarily act as hypnotics and vice versa.
Small, volatile molecules which induce anaesthesia (e.g. alcohols, halothane, ether etc) have been known for many years and are, or have been, commonly used to v 2 } 4 induce and maintain anaesthesia prior to, and during, elective surgery etc. However many conventional anaesthetics have various disadvantages. These include: (I) marrow concentration range over which the agent is effective (too little and the subject regains sensitivity to external stimuli whereas too much results in coma or death); 2) slow recovery following anaesthesia, 3) common side effects such as respiratory depression, cardiovascular instability and vomiting; and 4) uncommon but life threatening side-effects such as malignant hyperpyrexia.
Therefore there is a need to provide compounds which may be used as, or with anaesthetics, which obviate or mitigate disadvantages associated with the prior art.
According to a first aspect of the present invention, there is provided the use ) of a compound which modulates Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for regulating anaesthesia.
DSIP is a nonapeptide (which can exist in linear or cyclic form) with the . amino acid sequence:
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
DSIP was discovered in the 1970’s and has been proposed for sleep induction (for which it has had only limited success) and for treating drug addicts during drug withdrawal. However it has not previously been associated with anaesthesia and we have found that compounds which modulate DSIP activity are able to regulate anaesthesia.
DSIP may cause a reduction in brain metabolism which may be associated with a changed level of consciousness. However, the inventors have established that the reduction in brain metabolism seen with anacsthesia leads to a change in consciousness which is not typical of normal sleep. In fact, following DSIP treatment
So EEN ¢ J WO 00/45832 PCT/GB00/00281 there is a decrease in the amount of Rapid Eye Movement sleep and an increase in delta wave activity. The inventors have correlated these changes with the anaesthetised state and have therefore established that compounds which modulate
DSIP activity may be used according to the first aspect of the invention. The inventors further believe that DSIP may be important in the induction of hibernation and the reduction of brain metabolic activity during hibernation and similar states.
The inventors believe that DSIP is an endogenous “anaesthetic-like” substance which modulates neurotransmission and brain activity. This belief is founded upon observations made whilst conducting studies using PET to assess metabolic activity changes that occur in various areas of the brain during anaesthesia with conventional anaesthetic agents. The invention arose from the realisation that the areas of the brain ’ in which ‘there were changes in metabolic activity in response to a conventional anaesthetic agent were the same areas where DSIP has been shown to be located using :
J - immunohistology techniques. a Although we do not wish to be bound by any hypothesis, we believe that compounds which modulate DSIP activity are effective because they regulate binding : . of ligands with a neuromodulatory binding site on neuroreceptors which have been linked to the regulation of anaesthesia (e.g. the site described by Mihic et al. (1997) } Nature 389 p385-389 on GABA, receptors and glycine receptors). We believe binding of DSIP to these receptors modulates signalling from these receptors and thereby regulates the level of brain metabolism and the level of anaesthesia. : Our hypothesis that DSIP acts as an anaesthetic was confirmed by experiments which established that administration of DSIP induces anaesthesia and also prolongs anaesthesia induced by other anaesthetic agents. For instance, anaesthesia following a 7mg/kg iv bolus of propofol was approximately 28% longer in animals pretreated with DSIP (Img/kg IP, 15 mins prior to the propofol bolus) compared to animals treated with propofol alone. Further experimental data illustrating the efficacy of
DSIP, and related compounds, is presented in the Example below.
o 4 | ’
According to a first embodiment of the first aspect of the invention, we have found that compounds which increase DSIP activity may be administered alone, or preferably in combination with certain other anaesthetic agents, to induce or maintain anaesthesia. When used as part of a regime to induce anaesthesia, compounds which increase DSIP activity may be administered ai (he time of induction or at an earlier time as part of a regimen of pre-medication.
Several classes of compound which are capable of increasing DSIP activity may be used according to the invention. Such compounds include agonists or partial agonists of DSIP neuromodulatory binding sites, agents which enhance the release of endogenous agonists of DSIP neuromodulatory binding sites, agents which enhance the synthesis of endogenous agonists of DSIP neuromodulatory binding sites, agents which attenuate the breakdown (or removal/sequestration) of endogenous DSIP ’ agonists, agents which increase DSIP expression or activity and agents which enhance the mechanisms involved in signal transduction between the ligand bound DSIP ) binding site and effector systems.
Preferred compounds which increase DSIP activity are DSIP agonists and include DSIP per se and derivatives and/or pharamaceutically acceptable salts thereof. .
Preferred DSIP agonists which may be used according to the first embodiment of the first aspect of the invention include the phosphorylated nonapeptides disclosed in British Patent No. 2 0600 511. (which are incorporated herein by reference).
Biologically active fragments of DSIP, biologically active DSIP derivatives and larger peptides comprising the nonapeptide (or biologically active fragments and derivatives thereof) are also preferred compounds for use according to the first embodiment of the first aspect of the invention. For example a preferred derivative of
DSIP is Cyclo(-GLY-I>SIP) which is described by Nekrasov et al. (Biochem. Mol.
Biol. Int. 1996:38 p739-745). This derivative is more lipophilic than DSIP and crosses the blood brain barrier more readily. Cyclo (-GLY-DSIP) is particularly useful for rapid induction of anaesthesia.
‘ i WO 00/45832 PCT/GB00/00281
It will be appreciated that non-peptide compounds which mimic peptide DSIP agonist activity (which may be isolated from nature or rationally designed) may also be used.
Compounds which modulate DSIP activity may be used in a method of inducing anaesthesia comprising administering to a patient to be anaesthetised an effective amount of a compound which promotes DSIP activity to induce at least part of the desired level of anaesthesia. :
We believe that DSIP (and functional analogues thereof) induce or maintain anaesthesia according to the first embodiment of the first aspect of the invention for the following reasons: 2 ~~~ (1) It is a neuromodulator, not necessarily a neurotransmitter, which we : “ believe influences a transmembrane binding site on the GABA, glycine and possibly : other receptors in a manner consistent with a modulator working via the same site as the ethanol site and/or the enflurane anaesthetic site. : 4 : ~ (2) It is an anticonvulsant. } . ] (3) It has analgesic properties. We believe DSIP acts as an analgesic because it promotes the release of met-enkephalin. ) (4) Studies to investigate a possible action of DSIP in sleep promotion have shown that it does not induce normal sleep stages but promotes delta wave activity on the electroencephalograph as do many anaesthetics. During anaesthesia the electroencephalograph shows a complex pattern which may include a delta wave component but this pattern is distinct from that seen during natural sleep stages. (5) It may regulate excitation and inhibition within the brain. It may modulate thermoregulation, as do general anaesthetics.
The analgesic properties of the compounds (3 above) represents a particular advantage of compounds used according to the first embodiment of the first aspect of the invention. Under certain circumstances the analgesic activity of a compound may outlast the anaesthetic action. This is of particular benefit as it will promote pain relief
£ 6 | ’ during a recovery period following surgery etc. Furthermore it will be appreciated that the analegesia promoted by the compounds is not associated with respiratory depression (a common side-effect of many known analgesics e.g. morphine).
The inventors have found that compounds which increase DSIP activity are particularly useful for treating patients who require long term ventilation in the intensive care setting. A problem associated with such patients relates to the long term maintenance of an adequate state of anaesthesia such that the patient is maintained pain free and can be ventilated. Extensive clinical experience has shown that increasing doses of anaesthetic agents are required. In general, gaseous agents are not used because of a number of major drawbacks including pollution of the local environment. Continuous intravenous anaesthesia using propofol is often used.
However, accumulation of elements of the propofol formulation results in undesirable effects. Another major problem is that tolerance to the anaesthetic effects of propofol develops, in some cases rapidly, such that ever larger doses are required to maintain ) the patient. Finally, when the time comes to wean patients off the anaesthetic in order to wean the patient off the ventilator, the respiratory depression caused by conventional general anaesthetics is a major problem. The use of compounds that increase DSIP activity in this clinical setting has particular advantages because . increased DSIP activity does not cause respiratory depression. Furthermore tolerance has not been observed to the effects of the naturally occurring hormone. In addition,
DSIP has activities that will confer additional benefits over many conventional anaesthetics as follows: 1) DSIP has been shown to have analgesic activity of its own, possibly through the release of met enkephalin; (pain is frequently a prominent problem in the long term ventilated patient); and 2) DSIP has been shown to have a beneficial effect on the adaptive responses to stress (the intensive care setting is extremely stressful).
We have found that compounds which increase DSIP activity are also particularly useful as adjuncts to other anaesthetics. When given in conjunction with other anaesthetics, compounds that increase DSIP activity prolong the duration of i: i: WO 00/45832 PCT/GB00/00281 anaesthesia. Equally, when a compound according to the first embodiment of the first aspect of invention is used as an adjunct, a satisfactory depth of anaesthesia may be achieved at a reduced level of the other anaesthetic (compared to use of other anaesthetics alone). This has the advantage of reducing the risk of side effects and/or the discomfort associated with recovery from the use of higher amounts of anaesthetic compounds. For instance, known anaesthetics can be associated with respiratory depression whereby patients stop spontaneous breathing. DSIP is not associated with respiratory depression. Therefore, administration of DSIP with a reduced level of * known anaesthetic results in an acceptable level of anaesthesia without respiratory depression. :
The use of DSIP and other compounds according to the first embodiment of ’ the first aspect of the invention has the advantage that there is less risk of cardiovascular instability. Other advantages of using the compounds include: 1) the kinetics of DSIP in vivo is non-saturable (metabolism is by plasma ? and-other non-specific esterases); £ (ii) peptide compounds such as DSIP are not toxic and need not be used as a gas. Therefore there is less environmental pollution during manufacture, use and . disposal; and “+ (iii) compounds which promote DSIP activity also allow for instantaneous ) reversal, or at least quicker reversal, of general anaesthesia thereby further improving or climinating anaesthetic recovery times and improving anaesthetic safety (e.g. the use of DSIP as an anaesthetic cofactor in combination with propofol helps smooth out propofol induced anaesthesia and allows fewer intraoperative side effects)
DSIP is degraded by a number of non-specific peptidases including
Angiotensin Converting Enzyme (ACE). Therefore it is preferred for some applications that compounds according to the first embodiment of the first aspect of the invention are formulated with (or co-administered with) ACE inhibitors in order that DSIP activity may be potentiated. This is preferred when DSIP needs to be used for relatively long periods of time (e.g. anaesthesia and analgesia during intensive care).
v 8g !
According to a second embodiment of the first aspect of the invention compounds may be used which decrease DSIP activity.
Compounds according to the second ewbodiment of the first aspect of the invention may be used for increasing brain activity for inducing recovery from anaesthesia.
Several classes of compound which are capable of decreasing DSIP activity may be used according to the second embodiment of the first aspect of the invention.
Such compounds include antagonists or partial agonists of DSIP neuromodulatory binding sites, agents which inhibit the release of endogenous agonists of DSIP neuromodulatory binding sites, agents which inhibit the synthesis of endogenous ’ agonists of DSIP neuromodulatory binding sites, agents which promote the breakdown (or removal/sequestration) of endogenous DSIP agonists, agents which : decrease DSIP expression or activity and agents which inhibit the mechanisms involved in signal transduction between the ligand bound DSIP binding site and effector systems.
Preferred compounds which decrease DSIP activity are DSIP anatagonists and include melatonin, dalargin and neokyotorphin.
A preferred use of compounds which decrease DSIP activity is to promote recovery from anaesthesia. Thus, immediately before an operation, compounds according to the first embodiment of the first aspect of the invention may be used (alone or in conjunction with another anaesthetic) to anaesthetise a subject and then, once the procedure has been completed, compounds according to the second embodiment of the first aspect of the invention may be used to expedite recovery from anaesthesia.
Brain activity may be regulated with compounds which modulate DSIP activity according to either embodiment of the first aspect of the invention as a a 4 ¥ WO 00/45832 PCT/GB00/00281
A, monotherapy or in combination with other agents. For instance, anaesthesia may be induced with compounds according to the first embodiment of the first aspect of the invention alone (a monotherapy) or in combination with other known anaesthetic agents (e.g. combination therapy with a DSIP agonist as an anaesthetic cofactor for propofol or with a gaseous agent to reduce MAC. MAC being the Minimum Alveolar
Concentration of anaesthesia necessary to achieve loss of movement to a noxious stimulus in 50% of subjects). : When the compounds are used in combination with other agents, a lower dose of that agent may be required. This will reduce the incidence and severity of side- effects known to be caused by such agents. The dose requirements are typically reduced by 20 — 50% depending upon the specific combination used. ; + The compounds used according to the first aspect of the invention may take a 3 : number of different forms depending, in particular on the manner in which the i composition is to be used. Thus, for example, the composition may be in the form of oo a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, : micelle, liposome or any other suitable form that may be administered to a person or ) animal. It will be appreciated that the vehicle of the composition of the invention should be one which is well tolerated by the subject to whom it is given and enables delivery of the compounds to the target tissue.
Preferred formulations include sterile, isotonic solutions for injection and micronised powders with excipients for oral inhalation.
The compounds may be used in a number of ways. For instance, systemic administration may be required in which case the compound may be contained within a composition which may for example be administered by injection into the blood stream. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion). The compounds may also so be administered by inhalation. Alternatively : the compound may be ingested orally in the form of a tablet, capsule or liquid.
a /
Compounds modulating DSIP activity may be administered centrally by means of intracerebral, intracerebroventricular, or intrathecal delivery.
It will be appreciated that the amount of 2 compound required is determined by biological activity and bioavailability which in turn depends on the mode of administration, the physicochemical properties of the compound employed and whether the compound is being used as a monotherapy or in a combined therapy. The frequency and/or rate of administration will also be influenced by the above mentioned factors and particularly the half-life of the compound within the subject being treated. It will be appreciated that an anaesthetist will need to monitor the depth of anaesthesia of a subject during anaesthesia and adjust the required dose of the compound as required.
Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. in vivo experimentation, clinical trials etc), may be used ) to establish specific formulations of compositions and precise therapeutic regimes.
Generally, a dose of between 0.01 pg/kg of body weight and 1.0 g/kg of body weight of a compound which modulates DSIP activity may be used for the regulation . of brain activity depending upon which specific compound is used and the reason for regulating activity. For instance, a suitable dose of a DSIP agonist will be in the range of between 1.0 pg/kg and 1.0 mg/kg (preferably 20 - 400ug/kg). Purely by way of example a suitable dose of DSIP for use in combination with propofol (e.g. 7mg/kg 1.V. bolus) for inducing anaesthesia is between 0.01mg and 100 mg/kg and preferably between 0.02 mg/kg and 10 mg/kg.
Administration may be required frequently or continuously depending upon the requirements of an anaesthetist. By way of example between 1pg/kg/hr and lg/kg/hr, and preferably between 10pg/kg/hr and 100mg/kg/hr of DSIP may be required to maintain anaesthesia.
; ot WO 00/45832 PCT/GB00/00281
Vdd
According to a second aspect of the present invention, there is provided a method of regulating anaesthesia comprising administering to a subject in need of treatment a compound which modulates Delta-Sleep Inducing Peptide activity.
The abovementioned compounds which modulate DSIP activity according to the first aspect of the invention may be used according to the method of the second aspect of the invention.
According to a third aspect of the present invention there is provided a method of evaluating the anaesthetic needs of a subject to be anaesthetised comprising assaying a sample taken from the subject for the presence of Delta-Sleep Inducing
Peptide.
By “anaesthetic needs” we mean an assessment of the dose of an anaesthetic ; : required to induce or maintain a desired level of anaesthesia.
We have found that anaesthetic dose requirements are directly related to
J endogenous levels of DSIP. Thus a pre-operative assay of DSIP levels in a subject : } (e.g. a simple urine or blood test screening for DSIP) provides an anaesthetic dosage guide for predicting anaesthetic requirements. Higher than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have lower than average anaesthetic requirements. Lower than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have higher than average anaesthetic requirements.
It will be appreciated that the normal range for endogenous DSIP will depend upon the assay employed and the population studied. Purely by way of example DSIP levels may be assessed using the assay described by Seiftritz ef al. (Peptides 1995; 16 (8); p1475 — 1481). Using this assay the range of DSIP in blood is approximately 0.1 — 11 ng/ml. Therefore subjects with DSIP levels greater than about 5.0 ng/ml are likely to need less anaesthetic than normal whereas subjects with DSIP levels less than about 5.0 ng/ml are likely to require more anaesthetic than normal.
- f
A suitable assay for measuring DSIP levels in a sample is a quantitative immunoassay utilising antibodies raised against DSIP. For instance, the enzyme immunoassay described by Kato ef a. (Neuroendocrinology 1984:39:p39-44) may he adapted for usc as a pre-operative test 10 evaluaie anaesthetic requirements. An alternative assay which may be used according to the third aspect of the invention is a radicimmunoassay (e.g. as described by Sciftitz ef al. Supra). Ii is preferred that the assay mediates a colourmetric change which may be interpreted by eye or spectrophotometrically.
The sample is most suitably a blood or urine sample.
Such a method may be used pre-operatively to evaluate the anaesthetic needs ) of elective surgical patients.
According to one embodiment of the third aspect of the invention, an anaesthetist, nurse or theatre technician may test a blood or urine sample from a subject a short while (approximately 30 minutes or less) before anaesthesia to evaluate the anaesthetic needs of the subject. This test may be by means of inserting into the sample } a dip-stick which undergoes a colour change (depending upon the DSIP levels in the sample). An anaesthetist can then interpret the measured levels and adapt the anaesthetic regime accordingly.
The invention will be further illustrated by the following non-limiting Example.
, fa WO 00/45832 PCT/GB00/00281
Qy
Experiments were performed in rodents to evaluate the effect of DSIP on anaesthesia induced by propofol.
Methods
Nine female Sprague-Dawley rats weighing 230 to 287g had free access to water and rat Purina chow. All animals were maintained, cared for, and handled in accordance with IACUC animal utilization policy. Animals were divided into two groups to test the interactions between DSIP and the intravenous anaesthetic agent propofol (n=5) or the inhalational anaesthetic agent isoflurane (n=4). For the propofol test, rats were randomly selected to receive either Delta-sleep inducing peptide (Peninsula Labs, CA) 1 mg/kg i.p. in 3 ml of sterile water or just 3 ml of sterile water i.p. alone (placebo) 15 minutes prior ) to injection of propofol (Trademarks: Diprivan or Rapinoivet) 7 mg/kg i.v. into a tail vein over approximately 10 s. Following injection of propofol animals were tested for : loss of righting reflex. On loss of righting reflex the animals were placed on their sides in the center of a large plastic bowl with a flat bottom. Sleep time was recorded as the time taken to regain righting with all 4 feet on the ground. The following week, those animals that had received DSIP now received placebo pretreatment and those that had received placebo now received DSIP pretreatment. Again sleep time was assessed for each rat, after giving each rat the identical dose of propofol that it had been given the previous week.
For the inhalational test, rats were placed on a rotating rod in the middle of an anaesthetizing chamber. The level of inhalational agent was slowly titrated upwards in 0.05% increments every 10-15 min until the rats could no longer walk forward on the rotating rod. At week one, rats were randomly selected to receive either DSIP 0.1 mg/kg i.p. 15 min prior to testing, or placebo. The following week rats were crossed over to the other treatment arm (i.e. placebo to DSIP and DSIP to placebo).
Data were analyzed with a paired two-tailed t-tests.
Results
Intraperitoneal injection of 1mg/kg DSIP did not cause any rat to locse consciousness. Rats did, however, display a paucity of movement almost immediately after i.p. injection of DSIP. The animals did appear to be under the influence of some pharmacologic elect following DSIP preireaimeni, perhaps best described by noting that the rats appeared to have a “vacant” look about them when left undisturbed. The animals would, however, move appropriately when approached, but then would quickly resume a crouched position when left alone.
Sleep times following propofol iv injection (7mg/kg) for each animal are shown in Table 1.
Table 1 animal Sleep time (Sec) Sleep time (Sec)
IE EN
Each animal slept longer when pretreated with DSIP. The mean sleep time for propofol alone was 477 +/- 158 Sec. The mean sleep time for DSIP pretreatment followed by propofol was 611 +/- 145. This difference was significant at the P<0.01 level and represents a mean 28% increase in sleep time.
The dose of isoflurane anaesthesia (chamber 1S0%) required to prevent each animal from being able to walk forward on a rotating rod is shown in Table 2.
g RA WO 00/45832 PCT/GB00/00281 (
Na
Table 2 animal Chamber iso % Chamber iso %
DSIP 0.1mg/kg placebo
CT ee] = ew pw wer
The mean (+/- SD) concentration of isoflurane that prevented animals from being able to walk on the rotarod following placebo alone was 0.26 +/- 0.06%. The DSIP pretreatment reduced this value 23% to 0.20 +/- 0.06%. This reduction was statistically oo significant at the p = 0.01 level. ‘ These data illustrate that DSIP was particularly effective when used as an adjunct to both propofol and isoflurane. Table 1 illustrates that DSIP prolongs the length of . anaesthesia whereas Table 2 illustrates that DSIP is able to lower the concentration of another anaesthetic which is required to induce anaesthesia.
Claims (13)
- : i 16 2 CLAIMSI. The use of a compound which modulates Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for regulating anaesthesia.
- 2. The use according to claim 1, wherein the compound promotes or mimics Delta-Sleep Inducing Peptide activity and the medicament promotes or induces anaesthesia.
- 3. The use according to claim 2 wherein the compound is for use in conjunction with another anaesthetic agent.
- 4. The use of a compound which promotes Delta-Sleep Inducing Peptide activity for the manufacture of a medicament for promoting or inducing sedation. :
- 5. The use according to any one of claims 2 - 4, wherein the compound is Delta- Sleep Inducing Peptide or biologically active fragments and derivatives thereof.
- 6. The use according to claim 5 wherein the compound is a nonapeptide with the amino acid sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu - or biologically active fragments and derivatives thereof.
- 7. The use according to claim 6 wherein at least one amino acid or derivative thereof is phosphorylated.
- 8. The use according to claim 1, wherein the compound inhibits Delta-Sleep Inducing Peptide activity and the medicament promotes or induces recovery from anaesthesia.a, ® WO 00/45832 PCT/GB00/00281 dl : AN 17 iY )
- 9. A method of regulating anaesthesia comprising administering to a subject in need of treatment a compound which modulates Delta-Sleep Inducing Peptide activity. :
- 10. A method of evaluating the anaesthetic needs of a subject to be anaesthetised comprising assaying a sample taken from the subject for the presence of Delta-Sleep Inducing Peptide.
- 11. The method according to claim 10, wherein the sample is a blood or urine sample.
- 12. The method according to claim 10 or 11, wherein higher than average ) endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have lower than average anaesthetic requirements.
- 13. The method according to claim 10 or 11, wherein lower than average endogenous levels of Delta-Sleep Inducing Peptide assayed from the sample indicate the subject will have higher than average anaesthetic requirements.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9902469.7A GB9902469D0 (en) | 1999-02-05 | 1999-02-05 | Brain metabolism |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200106256B true ZA200106256B (en) | 2002-07-30 |
Family
ID=10847090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200106256A ZA200106256B (en) | 1999-02-05 | 2001-07-30 | Regulation of anaesthesia. |
Country Status (3)
Country | Link |
---|---|
EA (1) | EA200100861A1 (en) |
GB (1) | GB9902469D0 (en) |
ZA (1) | ZA200106256B (en) |
-
1999
- 1999-02-05 GB GBGB9902469.7A patent/GB9902469D0/en not_active Ceased
-
2000
- 2000-02-01 EA EA200100861A patent/EA200100861A1/en unknown
-
2001
- 2001-07-30 ZA ZA200106256A patent/ZA200106256B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA200100861A1 (en) | 2002-02-28 |
GB9902469D0 (en) | 1999-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6562855B1 (en) | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist | |
JP5863650B2 (en) | Method for treating pain | |
JP2003529541A6 (en) | Anesthetic preparation containing NMDA antagonist and α2 adrenergic agonist | |
Seddighi et al. | The effect of midazolam on the end-tidal concentration of isoflurane necessary to prevent movement in dogs | |
Klepstad et al. | Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post‐herpetic neuralgia | |
Cunningham et al. | Dissociation of experimentally induced drinking behavior by ibotenate injection into the median preoptic nucleus | |
Brackley et al. | Oxytocin receptor activation rescues opioid-induced respiratory depression by systemic fentanyl in the rat | |
KR20050104383A (en) | Estradiol metabolites for the treatment of pulmonary hypertension | |
AU2445900A (en) | Regulation of anaesthesia | |
Mazarati et al. | Felbamate in experimental model of status epilepticus | |
Guarnieri et al. | Subcutaneous implants of a cholesterol-triglyceride-buprenorphine suspension in rats | |
ZA200106256B (en) | Regulation of anaesthesia. | |
AU1152301A (en) | Treatment of dyskinesia | |
US20030064932A1 (en) | Methods of treatment comprising administration of Substance P | |
US11013873B2 (en) | Methods for treating patients with impaired awareness of hypoglycemia | |
AU2001296493B2 (en) | Use of neuropeptide-Y antagonists in treatment of alcoholism | |
WO2022182779A1 (en) | Methods and therapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches | |
Guindon et al. | The antinociceptive effects of local injections of propofol are mediated by cannabinoid CB1 and CB2 receptors: A-599 | |
AU2001296493A1 (en) | Use of neuropeptide-Y antagonists in treatment of alcoholism | |
Strumper et al. | Amitriptyline and fluoxetine inhibit human NMDA receptor signaling: A-783 | |
MXPA96003766A (en) | Methods of administering n-substituted benzamides or phenothiazines |